Shares of Danaher Corporation (NYSE:DHR) dropped as much as 16% in regular trading yesterday after completing the spinoff of its Veralto unit. DHR …

No summary available.

The conglomerate has completed the spinoff of its environmental and applied solutions segment into a new company, Veralto.

Danaher Corporation completes spin-off of Veralto, its Environmental & Applied Solutions business. Read what DHR and VLTO stock investors need to know.

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. SmileDirectClub, Inc. (NASDAQ: SDC ) shares tumbled 64.1% to $0.1489 in pre-market trading. SmileDirectClub filed for bankruptcy just a few years after its remarkable $1.35 billion IPO. Brooge Energy Limited (NASDAQ: BROG ) shares dipped 9.8% to $5.02 in … Full story available on Benzinga.com

Abcam founder and shareholder Jonathan Milner opposes the company''s sale and is looking at various options. Headwaters Capital is also against the dea.

During the last session, Danaher Corp. (NYSE:DHR)’s traded shares were 3.22 million, with the beta value of the company hitting 0.81. At the end of the trading day, the stock’s price was $248.10, reflecting an intraday gain of 0.37% or $0.91. The 52-week high for the DHR share is $283.63, that puts it down -14.32 … After Danaher Corp. (NYSE: DHR) Surges -23.34% From Highs, What Will It Look Like? Read More »

Danaher''s (DHR) ability to deliver returns for shareholders appears stronger than ever.

Jonathan Milner blasted the ''low ball'' offer for the Cambridge-based company, which is one of the most successful British biotech firms.

KeyBanc Capital Markets analyst Paul Knight reiterated the Overweight rating on Danaher Corporation (NYSE: DHR ), lowering the price target to $300 from $325. Knight notes that after a strong period in 2021 and early 2022, the life science tools sector, including DHR, has been underperforming in FY23. The analyst adds that there have been headwinds due to destocking in consumables used in biological production (such as filters and single-use bags), leading to reduced demand as customers worked down stockpiles in FY23. Additionally, funding for early-stage biotech customers has dried up as exit the pandemic, and weakness in China brought biotech spending to a slow pace during the 2Q23 results period, the analyst cautioned. However, on the positive side, Knight writes Danaher has a high-growth and high-margin profile following the Veralto (VLTO) spin. For … Full story available on Benzinga.com